The truth is, none of us retail NWBO investors have seen the raw data. And even if we did, we'd have no idea how to properly interpret it. You'd need an MD and 10+ years of clinical experience with GBM to accurately interpret this data.
However, the 70+ oncologists who were involved in the trial HAVE seen the raw data, DO possess the qualifications to interpret it, and I'm sure have been debating it internally for quite some time. This will become more and more clear over time, but the oncology world appears to be over the moon about this trial. We should all take great confidence in that.
The financial world will want to see a journal article and will want to see regulatory approval. When that happens they will come around to what we have known all along. Adding in those two vectors will completely change the trajectory of this company and ensure the survival of this technology.
Market Data 
Markets 
AI
